Table 1.

Main features of the included study population: n = 84 patients with GD or GC arisen in a histopathological background of MF-AG or CR-AG

	All patients MF-AG and CR-AG n = 84 (100%)	MF-AG n = 45 (53.6%)	CR-AG n = 39 (46.4%)	P
Age at AG diagnosis
Median, range	70.0, 33–90	70.0, 33–90	70.0, 48-86	0.46
Mean, SD	69.3, 10.6	70.0, 10.8	68.5, 10.4	0.50
Females, n (%)	54.8	42.2	69.2	0.01
GD-GC diagnosis concomitant to AG diagnosis	35.7	33.3	38.5	0.63
AG diagnosis >1 yr regarding GD-GC diagnosis median, range	4, 1-17	4, 1-12	5, 1-17	0.90
Mean, SD	5.5, 4.0	5.1, 3.2	6.0, 4.8	0.54
Hp eradication treatment before diagnosis of GD-GC	16.7	20.0	12.8	0.30
Positivity toward parietal cell autoantibodies	60.0	51.5	69.7	0.13
First-degree family history for GC	15.2	14.7	15.6	0.92
Active or previous use of proton pump inhibitors	56.4	56.2	56.5	0.98
Active or previous smoking habit	30.4	9/30 (30.0)	30.8	0.95
Type of anemia			n = 31
Iron-deficiency	25.8	30.3	19.4	0.31
Pernicious	18.8	9.1	29.0	0.04
Mixed	9.4	12.1	6.5	0.44
None	46.9	48.5	45.2	0.79

Data expressed as % when not otherwise indicated.

AG, atrophic gastritis, CR, corpus-restricted; GC, gastric cancer; GD, gastric dysplasia; Hp, Helicobacter pylori; MF, multifocal.